Abbreviated New Drug Application (ANDA) and 505(b)(2)
When it comes to generic drugs, speed matters. Starting from 1971, Gyma has enabled pharmaceuticals to launch over a thousand first-to-market APIs under ANDA filings.
For our partners looking to create new combinations from known APIs, make current drugs more effective or introduce new administration routes for older drugs, Gyma can simplify and expedite the 505(b)(2) application process. This helps deliver access to the best pharmaceutical care worldwide. Under the 505(b)(2) application, Gyma has enabled over 40 novel drugs to come to the markets across the world.